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SHORT COMMUNICATION
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In the near future, the overlap of Coronavirus disease 2019 (COVID-19) and dengue epidemics is a concrete threat in tropical 
regions. Co-epidemics of COVID-19 and dengue could be an overwhelming challenge for health systems in low- and middle-
income countries. In this work, we investigated potential serological cross-reactions between COVID-19 and dengue patients. 
Among 32 COVID-19 positive sera, no positive Dengue virus (DENV) IgG/IgM results were observed. On the other hand, one 
false-positive result was observed among 44 DENV-positive sera tested for COVID-19 antibodies with each of the two rapid tests 
used. Further data on accuracy of COVID-19 diagnostic test are urgently warranted.
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Since December 2019, Coronavirus disease 2019 (CO-
VID-19), caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), emerged in the interna-
tional scene as a major public health concern. COVID-19 
pandemic is having a disrupting impact on health systems 
throughout Asia, Europe and America.(1) At the same time, 
a large outbreak of dengue is ongoing in Latin American 
countries, with several deaths being recorded.(2)
In the near future, the overlap of COVID-19 and den-
gue epidemics is a concrete threat in tropical regions.(3,4) 
COVID-19 and dengue share several features of clini-
cal and laboratory presentation, and differential diagno-
sis should rely on specific diagnostic tests.(5) Recently, 
two cases of false-positive results by rapid diagnostic 
test (RDT) for dengue in patients with SARS-CoV-2 
infection were reported from Singapore.(6) If serological 
cross-reactivity between patients with COVID-19 and 
dengue will be confirmed, it may result in a high num-
ber of misdiagnoses, with dangerous consequences both 
from the patients and from public health point of view.(7)
In order to further explore this possibility, we in-
vestigated potential serological cross-reactions be-
tween COVID-19 and dengue patients, by performing 
commercial assays for detection of anti-Dengue virus 
(DENV) and anti-SARS-CoV-2 antibodies on sera from 
well-characterised COVID-19- and dengue-positive pa-
tients, respectively.
A total of 32 anonymised sera, obtained from symp-
tomatic patients with COVID-19 diagnosed by positive 
anti-SARS-CoV-2 IgM/IgG (32/32, tested by 2019-
NCOV IgG/IgM Rapid Test Cassette, ScreenItalia, Peru-
gia, Italy) and/or RT-PCR for SARS-CoV-2 on nasopha-
ryngeal swab (26/32), were tested by Dengue Enzyme 
Linked Immune Assay (ELISA) DENV IgG-IgM (VIR-
CELL, Granada, Spain). Sera were collected and tested 
in Italy, at the Careggi University Hospital of Florence, 
where dengue is not endemic, and previous exposure to 
DENV was unlikely.
Moreover, 44 anonymised DENV-positive sera, from 
cases of acute dengue (27 of whom confirmed by NS1 an-
tigen positivity, plus 17 probable diagnosis with only IgM 
and IgG positivity), were tested by using COVID-19 IgG/
IgM Rapid Test Cassette (Orient Gene, Zhejiang, China) 
and 2019-NCOV IgG/IgM Rapid Test Cassette (ScreenI-
talia, Perugia, Italy). All DENV-positive sera were col-
lected from travellers, before SARS-CoV-2 emergence.
Among 32 COVID-19 positive sera, no positive 
DENV IgG/IgM results were observed. On the other 
hand, one false-positive result was observed among 44 
DENV-positive sera tested for COVID-19 antibodies 
with each method (in one case for IgG and IgM, and in 
another for IgG only), in two different samples.
Serological test for dengue are known to be affected 
by cross-reactivity issues in areas were multiple Flavivi-
rus, such as Zika, Yellow fever or Japanese encephalitis 
virus are circulating. The risk of false-positive results 
is reduced when dengue IgM/IgG testing is paired with 
NS1 antigen capture.(8)
According with our results, the concern about false-
positive dengue serology in COVID-19 patients could 
be downsized, at least when an ELISA is used. On the 
other hand, COVID-19 false-positive results are possi-
ble in patients with DENV infection, although at a low 
rate and variably using different RDTs for COVID-19. 
It should be also considered that these COVID-19 false-
positive results may reflect different aspecific cross-
reactivity, not necessarily related to DENV-specific 
antibodies.(9) Of course, this is a preliminary study on a 
limited number of samples, which need to be validated 
on a wider population.
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In low- and middle-income countries, where arbovi-
ruses and other common tropical diseases are highly en-
demic, SARS-CoV-2 spread will represent an additional 
challenge for clinicians.(10,11) In particular, co-epidemics 
of COVID-19 and dengue could be an overwhelming 
situation for health systems.(12) Further studies are war-
ranted to better elucidate the accuracy of commercially 
available RDTs for SARS-CoV-2 antibodies detection 
and their role within the strategy for COVID-19 diagno-
sis and control.
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